Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study

Retina

Volumn 36, Issue 6, 2016, Pages 1143-1152

  Maturi, Raj K ^a   Pollack, Ayala ^b   Uy, Harvey S ^c   Varano, Monica ^d   Gomes, Andre M V ^e   Li, Xiao Yan ^f   Cui, Harry ^g   Lou, Jean ^f   Hashad, Yehia ^f   Whitcup, Scott M ^h  

^a MIDWEST EYE INSTITUTE   (United States)

^b KAPLAN MEDICAL CENTER   (Israel)

^c Pacific Eye and Laser Institute   (Philippines)

^d IRCCS FONDAZIONE BIETTI   (Italy)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f ALLERGAN INC   (United States)

^g AVANIR PHARMACEUTICALS   (United States)

^h JULES STEIN EYE INSTITUTE   (United States)

Author keywords

corticosteroid; diabetic retinopathy; drug delivery; intraocular pressure; intravitreal; macular edema; sustained release implant

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; DEXAMETHASONE; PROSTAGLANDIN; ANTIHYPERTENSIVE AGENT; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; ARTICLE; CENTRAL RETINAL THICKNESS; CLOSED ANGLE GLAUCOMA; DEVICE SAFETY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; FILTERING OPERATION; GLAUCOMA; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; INTRAVITREAL IMPLANT; LASER SURGERY; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OPEN ANGLE GLAUCOMA; OPTIC NERVE ATROPHY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); VISUAL ACUITY; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIAGNOSTIC IMAGING; DRUG EFFECTS; DRUG IMPLANT; FEMALE; INTRAOCULAR PRESSURE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODAL IMAGING; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETREATMENT;

AGED; ANTIHYPERTENSIVE AGENTS; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; MULTIMODAL IMAGING; OCULAR HYPERTENSION; RECURRENCE; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TONOMETRY, OCULAR;

EID: 84957927695     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000001004     Document Type: Article

References (34)

1. Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013;4:151-169.
2. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
3. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011;30:343-358.
4. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009;116:73-79.
5. Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 1999;96:10836-10841.
6. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999;14:223-232.
7. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-315.
8. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-1444.
9. Felinski EA, Antonetti DA. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res 2005;30:949-957.
10. Standards of medical care in diabetes-2009. Diabetes Care 2009;32(suppl 1):S13-S61.
11. Nguyen QD, Shah SM, Heier JS, et al; READ-2 Study Group. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2009;116:2175-2181.e1.
12. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078-1086.e2.
13. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011; 118:1819-1826.
14. Sav A, King MA, Whitty JA, et al. Burden of treatment for chronic illness: a concept analysis and review of the literature. Health Expect 2015;18:312-324.
15. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
16. Bhisitkul RB, Campochiaro PA, Shapiro H, Rubio RG. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. Ophthalmology 2013;120:1057-1063.
17. Boyer DS, Yoon YH, Belfort R Jr, et al; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-1914.
18. Civerchia LL, Balent A. Treatment of pseudophakic cystoid macular edema by elevation of intraocular pressure. Ann Ophthalmol 1984;16:890-894.
19. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina 2008;28:573-580.
20. Benz MS, Albini TA, Holz ER, et al. Short-Term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006;113:1174-1178.
21. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 2009; 23:181-185.
22. Kiddee W, Trope GE, Sheng L, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol 2013;58:291-310.
23. Demirel S, Yanik O, Batioglu F, Ozmert E. Intraocular pressure changes related to intravitreal injections of ranibizumab: analysis of pseudophakia and glaucoma subgroup. Int Ophthalmol 2015;35:541-547.
24. Aref AA. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin Ophthalmol 2012;23:105-110.
25. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-1114.
26. Mathalone N, Arodi-Golan A, Sar S, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012;250: 1435-1440.
27. Singh RS, Kim JE. Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents. Drugs Aging 2012;29:949-956.
28. Skalicky SE, Ho I, Agar A, Bank A. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging 2012;43:328-334.
29. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012;21:241-247.
30. Yannuzzi NA, Patel SN, Bhavsar KV, et al. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol 2014;158:319-327.e2.
31. Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010;30: 887-892.
32. Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol 2011; 129:914-920.
33. Campochiaro PA, Brown DM, Pearson A, et al; FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-2132.
34. Nehme A, Lobenhofer EK, Stamer WD, Edelman JL. Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics 2009;2:58.